INOVIO PHARMACEUTICALS, INC.
INO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INO
INOVIO PHARMACEUTICALS, INC. is a clinical-stage biotechnology company focused on developing DNA-based medicines, with its lead candidate INO-3107 under FDA review for Recurrent Respiratory Papillomatosis (RRP) and a PDUFA date of October 30, 2026.
Key risk: Dependence on INO-3107 approval
BioSniper Score
Based on 5 of 6 signals
Market Cap
$133.4M
Cash Runway
6.2 moLead Asset
ino-3107 (Phase 1/Phase 2)Next Catalyst
PDUFA · Oct 30, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials · 1 catalyst for INOVIO PHARMACEUTICALS, INC..
Similar companies
INOVIO PHARMACEUTICALS, INC. is a clinical-stage biotechnology company focused on developing DNA-based medicines, with its lead candidate INO-3107 under FDA review for Recurrent Respiratory Papillomatosis (RRP) and a PDUFA date of October 30, 2026.
- Lead candidate INO-3107 has a BLA accepted for review under the Accelerated Approval Program for RRP, with a PDUFA date of October 30, 2026 [sec · filed 2026-04-07].
- As of June 30, 2026, the company reported cash & equivalents of $31.5M, no revenue, a net loss of $6.0M, and shareholders' equity of $24.1M [sec].
- Cash runway is expected to extend into late first quarter 2027, without giving effect to further capital raising activities [sec_mda · as of 2026-08-12].
- Accumulated deficit was $1.8 billion as of December 31, 2025, and the company expects to continue operating at a loss [sec_mda · as of 2026-03-12].
- Other pipeline candidates target HPV-related anal dysplasia, cancers with specific gene mutations, and an Ebola vaccine booster [sec_mda · as of 2026-05-13].
What works
- INO-3107 has received Breakthrough Therapy Designation from the FDA and Orphan Drug Designation from the EU, supporting its regulatory pathway [sec · filed 2024-04-11].
- The company has gained FDA alignment on the design of a planned Phase 3 trial for INO-3107, indicating regulatory clarity [sec_mda · as of 2026-05-13].
- INOVIO is advancing DNA-Encoded Protein (DPROT) and DNA-Encoded Monoclonal Antibody (DMAb) technologies, which have shown potential across multiple disease targets [sec_mda · as of 2026-05-13].
What to weigh
- The company has not generated any product revenues and does not expect material revenues unless INO-3107 or other candidates are approved and commercialized [sec_mda · as of 2026-05-13].
- Cash resources are insufficient to complete clinical development beyond INO-3107, and additional financing will be required for commercialization [sec_mda · as of 2026-03-12].
- Accumulated deficit of $1.8 billion continues to grow, and the company expects to operate at a loss for the near term [sec_mda · as of 2026-03-12].
- The company's ability to continue operations is dependent on obtaining additional capital in the future [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
INO-3107 BLA accepted under Accelerated Approval with PDUFA date October 30, 2026
“Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA) date October 30, 2026.”
SEC filings · April 7, 2026
Cash runway extends into late first quarter 2027
“We expect our cash runway, including the net proceeds from the July 2026 Offering, to extend into late first quarter 2027, without giving effect to any further capital raising activities that we may undertake.”
SEC MD&A · August 12, 2026
Accumulated deficit of $1.8 billion as of December 31, 2025
“As of December 31, 2025, we had an accumulated deficit of $1.8 billion, and we expect to continue to operate at a loss for the near term.”
SEC MD&A · March 12, 2026
No product revenues generated to date
“We have not generated any revenues from the sale of any products, and we do not expect to generate any material revenues unless and until we obtain marketing approval for and successfully commercialize INO-3107 and our other product candidates.”
SEC MD&A · May 13, 2026
Catalyst timeline
- 2026-10-30 · PDUFA · ino-3107 — FDA decision on the Biologics License Application for INO-3107 for Recurrent Respiratory Papillomatosis.
Risks & what to watch (4)›
Key risks
- Dependence on INO-3107 approval — The company's near-term prospects hinge on FDA approval of INO-3107; failure would significantly impact operations [sec_mda · as of 2026-05-13].
- Insufficient cash for full development — Current cash is insufficient to complete clinical development beyond INO-3107, requiring additional financing [sec_mda · as of 2026-03-12].
- Continued operating losses — Accumulated deficit of $1.8 billion and ongoing net losses strain financial resources [sec_mda · as of 2026-03-12].
- No product revenue history — The company has never generated revenue from product sales and may not do so for the foreseeable future [sec_mda · as of 2026-05-13].
What to watch
- FDA decision on INO-3107 BLA by PDUFA date October 30, 2026 [sec · filed 2026-04-07].
- Cash burn rate and any additional capital raising activities to extend runway beyond Q1 2027 [sec_mda · as of 2026-08-12].
- Progress of Phase 3 trial design alignment with FDA and European regulators for INO-3107 [sec_mda · as of 2026-05-13].
- Updates on pipeline candidates for HPV-related anal dysplasia and other indications [sec_mda · as of 2026-05-13].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run INOVIO PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INOVIO PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
6.2 months
D/E 10.30 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~61d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
98
Total value held
$60.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,339,614 | $16.3M |
| janus henderson group plc | 6,616,812 | $11.5M |
| vanguard capital management llc | 5,802,416 | $10.1M |
| d. e. shaw & co., inc. | 2,212,819 | $3.9M |
| adar1 capital management, llc | 1,470,108 | $2.6M |
| millennium management llc | 1,410,845 | $2.5M |
| adage capital partners gp, l.l.c. | 804,958 | $1.4M |
| geode capital management, llc | 801,504 | $1.4M |
| blackrock, inc. | 662,181 | $1.2M |
| renaissance technologies llc | 643,777 | $1.1M |
Showing top 10 of 98 institutional holders of INOVIO PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 17.9%
- Days to cover
- 4.9
- Shares short
- 12,768,874
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INO short interestGovernance
Frequently asked questions
What is the AI investment thesis for INOVIO PHARMACEUTICALS, INC.?
INOVIO PHARMACEUTICALS, INC. is a clinical-stage biotechnology company focused on developing DNA-based medicines, with its lead candidate INO-3107 under FDA review for Recurrent Respiratory Papillomatosis (RRP) and a PDUFA date of October 30, 2026.
What is INOVIO PHARMACEUTICALS, INC.'s lead drug candidate?
INOVIO PHARMACEUTICALS, INC.'s most advanced tracked candidate is ino-3107 (Phase 1/Phase 2) for Respiratory Papillomatosis.
What is INOVIO PHARMACEUTICALS, INC.'s next catalyst?
INOVIO PHARMACEUTICALS, INC.'s next tracked catalyst is a PDUFA event — "PDUFA Date: ino-3107" — expected October 30, 2026.
Who is the CEO of INOVIO PHARMACEUTICALS, INC.?
Dr. Jacqueline E. Shea Ph.D. is the chief executive officer of INOVIO PHARMACEUTICALS, INC. (INO).
Where is INOVIO PHARMACEUTICALS, INC. headquartered?
INOVIO PHARMACEUTICALS, INC. (INO) is headquartered in Plymouth Meeting, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.